Generic Name and Formulations:
Clomiphene citrate 50mg; scored tabs.
Indications for CLOMID:
Induction of ovulation.
50mg daily for 5 days beginning on the 5th day of menstrual cycle; max 3 courses. If ovulation does not occur after 1st course, increase dose to 100mg daily for 2nd course; max 100mg/day for 5 days. See full labeling.
Primary ovarian failure. Ovarian cysts. Uterine leiomyomas. Abnormal vaginal bleeding. Thrombophlebitis. Liver disease. Depression. Uncontrolled thyroid or adrenal dysfunction. Organic intracranial lesions (eg, pituitary tumor). Pregnancy (Cat.X).
Perform initial complete pelvic and endocrinologic exam. If ovarian enlargement occurs, hold dose until ovaries return to pretreatment size, and reduce dosage or duration of next course. Polycystic ovary syndrome. Discontinue if visual disorders occur. Metabolism disorders (eg, hypertriglyceridemia). Preexisting or family history of hyperlipidemia: monitor plasma triglycerides periodically. Nursing mothers.
Ovarian enlargement, vasomotor flushes, abdominal/pelvic discomfort/distention/bloating, nausea, vomiting, breast discomfort, visual symptoms (eg, blurred vision, lights, floaters), headache, abnormal uterine bleeding; multiple births, pancreatitis.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|